金城医药(300233.SZ)：子公司参与国家组织集采药品协议期满品种接续采购拟中选

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national centralized procurement for expiring drug agreements, with seven products, including Cefoperazone Sodium Injection and Ceftazidime Injection, expected to be selected for procurement [1] Group 1: Company Performance - The total sales revenue of the seven products expected to be selected for procurement in the first three quarters of 2025 is projected to be 414.46 million yuan, accounting for 21.45% of the company's total revenue during the same period [1] Group 2: Procurement Details - The procurement results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed procurement volume [1]